Cardiovascular diseases (CVDs) and sepsis are the leading cause of death worldwide. Efficient tools for reliable patient risk assessment, stratification and treatment guidance represent a clear unmet medical need.
Our biomarker research team is dedicated to the identification and development of novel biomarkers. Diagnostic tools can aid patient stratification as well as identification of patient groups that will most likely benefit from targeted therapies. Our novel biomarker DPP3 effectively predicts short-term organ dysfunction and disease severity in patients suffering from cardiovascular failure. DPP3 blood levels can be additionally used to monitor disease progression and guide treatment strategies. This newly developed immunoassay can be used alone or in combination with Procizumab treatment.
DPP3 is a highly conserved, ubiquitously expressed cytosolic peptidase. Upon diseases that are associated with necrotic events and cell death, as seen e.g. in acute heart failure, myocardial infarction, cardiogenic shock, sepsis, stroke or trauma, DPP3 is released into the bloodstream. In the blood, circulating DPP3 uncontrollably degrades its substrates, such as Angiotensin II and Enkephalin. As a result, the hormonal regulation exerted by these bioactive peptides is disrupted, which culminates in organ failure. Therefore, high DPP3 plasma concentrations have been shown to predict short-term organ dysfunction and mortality, while a reduction of circulating DPP3 concentrations to normal levels within 24 hours immensely improves patient prognosis .
“With the IB10 sphingotest® DPP3, an early prediction of short-term multi-organ failure is possible. The biomarker dynamic nature enables close patient monitoring and risk stratification, leading to improved outcome.”
The IB10 sphingotest® DPP3 allows the early diagnosis and monitoring of clinically relevant DPP3 released upon necrotic events in critically ill patients with a simple blood draw . With the IB10 sphingotest® DPP3, an early prediction of short-term multi-organ failure is possible. The biomarker dynamic nature enables close patient monitoring and risk stratification, leading to improved outcome. For more information, please see: https://sphingotec.com/nexus-ib10/.
 Deniau et al. (2019) Circulating dipeptidyl peptidase-3 is a myocardial depressant factor: dipeptidyl peptidase 3 inhibition rapidly and sustainably improves haemodynamics.
 Rehfeld et al. (2018) Novel Methods for the Quantification of Dipeptidyl Peptidase 3 (DPP3) Concentration and Activity in Human Blood Samples. JALM.